Stockscreener 앱 받기
8.85
0.45%
0.04
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
Is ARS Pharmaceuticals Inc. stock vulnerable to regulatory risksSwing Trade & Weekly High Return Opportunities - mfd.ru
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock - Seeking Alpha
Why hedge funds are buying ARS Pharmaceuticals Inc. stockJuly 2025 Reactions & High Win Rate Trade Alerts - mfd.ru
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® at 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting - Investing News Network
Needle-free epinephrine nasal spray may cut costs and boost patient preference - Stock Titan
ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis $SPRY - MarketBeat
Market Moves: Is INHDs ROE strong enoughWeekly Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
(SPRY) and the Role of Price-Sensitive Allocations - Stock Traders Daily
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Will ARS Pharmaceuticals Inc. stock recover after earningsWeekly Loss Report & Capital Efficiency Focused Ideas - mfd.ru
How Investors May Respond To ARS Pharmaceuticals (SPRY) Expanding EURneffy Pediatric Use Across Europe - Yahoo Finance
Aquestive leaps, despite receiving CRL for Anaphylm NDA - The Pharma Letter
ARS Pharma Gets Positive CHMP Opinion For 1 Mg EURneffy Nasal Spray - Nasdaq
Needle-free allergy rescue for kids wins key EU support - Stock Titan
US FDA declines to approve Aquestive's oral drug for allergic reactions - Reuters
Targets Report: Will OceanPal Inc benefit from geopolitical trendsCPI Data & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Lisanti Capital Growth LLC Sells 208,886 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Weekly Recap: Will ARS Pharmaceuticals Inc announce a stock splitJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
ARS Pharmaceuticals (NASDAQ:SPRY) Cut to Strong Sell at Zacks Research - MarketBeat
Repeat Offenders: Neffy, Anktiva Promotions Draw Another US FDA Untitled Letter After Crackdown - Citeline News & Insights
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Responsive Playbooks and the SPRY Inflection - Stock Traders Daily
Update Recap: Will ARS Pharmaceuticals Inc stock recover after earningsJuly 2025 Snapshot & Capital Efficient Trade Techniques - baoquankhu1.vn
Pullback Watch: Will ARS Pharmaceuticals Inc stock recover after earnings2025 Top Gainers & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
ARS Pharmaceuticals Reports Q3 2025 Financial Results - MSN
What ARS Pharmaceuticals (SPRY)'s neffyinSchools California Expansion Means For Shareholders - Sahm
Valuation Update: Is ARS Pharmaceuticals Inc a top pick in the sectorInsider Selling & Free High Return Stock Watch Alerts - baoquankhu1.vn
Aug Rallies: Can ARS Pharmaceuticals Inc generate free cash flowJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Pullback Watch: Is ARS Pharmaceuticals Inc attractive at current valuationJuly 2025 Action & Weekly Consistent Profit Watchlists - baoquankhu1.vn
What are ARS Pharmaceuticals Inc.’s earnings expectationsTrade Exit Report & Reliable Breakout Forecasts - mfd.ru
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free ... - nrtoday.com
California K-12 Schools Now Eligible for neffyinSchools - GlobeNewswire
ARS Pharmaceuticals, Inc. (SPRY) Investor Outlook: Analyzing the 171% Upside Potential for This Biotech Stock - DirectorsTalk Interviews
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Community Approval For Neffy Epinephrine Spray - simplywall.st
Understanding the Setup: (SPRY) and Scalable Risk - Stock Traders Daily
Is ARS Pharmaceuticals Inc a top pick in the sector2025 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Sell Signal: Is ARS Pharmaceuticals Inc stock a falling knife or bargain buy2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Targets Report: What analysts say about ARS Pharmaceuticals Inc stock2025 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 12.3%Should You Sell? - MarketBeat
Assessing ARS Pharmaceuticals (SPRY) Valuation After A 19.3% Single Day Share Price Jump - Yahoo Finance
There's No Escaping ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) Muted Revenues Despite A 25% Share Price Rise - 富途牛牛
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - simplywall.st
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating - Finviz
What's Going On With ARS Pharmaceuticals Stock Friday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Sahm
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpShould You Buy? - MarketBeat
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Approval Expands Neffy Allergy Market Reach - Sahm
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
What drives ARS Pharmaceuticals Inc stock priceVolatility Index Analysis & Access High Yield Alerts - earlytimes.in
ARS Pharmaceuticals, Inc.Common Stock (NQ: SPRY - FinancialContent
ARS Pharmaceuticals, Inc. (SPRY): Investor Outlook Reveals a Compelling 162% Upside Potential - DirectorsTalk Interviews
ARS Pharma’s neffy nasal spray approved in China... - The Pharma Letter
The Technical Signals Behind (SPRY) That Institutions Follow - Stock Traders Daily
ARS Pharmaceuticals Stock Pre-Market (+4.4%) : 'neffy' Nasal Spray Approved in China - Trefis
Is ARS Pharmaceuticals a buy? - Cantech Letter
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - simplywall.st
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg - Yahoo Finance
1.12%
0.87%
자본화:
|
볼륨(24시간):